Squarepoint Ops LLC Acquires New Holdings in Novavax, Inc. (NASDAQ:NVAX)

Squarepoint Ops LLC acquired a new stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 98,777 shares of the biopharmaceutical company's stock, valued at approximately $1,251,000. Squarepoint Ops LLC owned approximately 0.07% of Novavax at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in NVAX. Swedbank AB acquired a new position in shares of Novavax in the first quarter worth about $26,000. Banque Cantonale Vaudoise raised its position in shares of Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 2,500 shares during the period. Herr Investment Group LLC bought a new position in shares of Novavax in the first quarter valued at approximately $48,000. Alpine Global Management LLC bought a new position in shares of Novavax in the first quarter valued at approximately $49,000. Finally, Ameritas Investment Partners Inc. raised its position in shares of Novavax by 31.6% in the first quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 2,711 shares during the period. Institutional investors own 53.04% of the company's stock.

Analyst Upgrades and Downgrades

NVAX has been the topic of several research analyst reports. Jefferies Financial Group restated a "buy" rating and issued a $31.00 price objective on shares of Novavax in a research note on Wednesday. Bank of America lifted their price objective on Novavax from $12.00 to $18.00 and gave the company a "neutral" rating in a report on Friday, June 14th. B. Riley reissued a "buy" rating and set a $23.00 price objective (down from $25.00) on shares of Novavax in a report on Monday, August 12th. Finally, JPMorgan Chase & Co. lifted their price objective on Novavax from $8.00 to $9.00 and gave the company an "underweight" rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, Novavax currently has a consensus rating of "Hold" and a consensus target price of $18.33.

Novavax Trading Down 5.6 %

Shares of Novavax stock traded down $0.81 during trading on Friday, reaching $13.61. The company's stock had a trading volume of 7,537,471 shares, compared to its average volume of 10,301,194. The stock has a 50-day moving average price of $12.50 and a two-hundred day moving average price of $11.29. Novavax, Inc. has a one year low of $3.53 and a one year high of $23.86. The stock has a market capitalization of $1.91 billion, a P/E ratio of -4.29 and a beta of 2.04.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million during the quarter, compared to analyst estimates of $458.57 million. The firm's revenue was down 2.1% compared to the same quarter last year. During the same period last year, the company earned $0.58 earnings per share. As a group, sell-side analysts anticipate that Novavax, Inc. will post -1.04 EPS for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.